Celltech Chiroscience
Article Abstract:
Celltech Chiroscience was created from the merger of Chiroscience and Celltech. A stake in ChiroTech, the manufacturing divisioon, has been sold, bringing in 59 million pounds sterling. The company has additional cash reserves, and revenue from a number of sources, such as patents and the sale of Chirocaine. Celltech Chiroscience is also developing products using antibody technology from Celltech. There are also partnerships with pharmaceutical concerns. Biotechnology companies tend to involve risk, but Celltech Chiroscience is stronger than most.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Proteus
Article Abstract:
Proteus was able to carry out a rights issue in May 1996 and afterwards a change in sentiment among UK investors affected biotechnology companies. The cash raised from the share issue should help fund research. The cancellation of an agreement with SmithKline Beecham was not mentioned in the rights document. ML Laboratories is the new backer of Proteus and will help fund development of products. ML also has share options, refusal rights on compounds, and sub-licensing rights.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Tellem Worldwide. STC Associates. Sciens Worldwide PR
- Abstracts: Grave offence. Shares all round. All in the family
- Abstracts: McKechnie. Victrex. British Vita
- Abstracts: Death and taxes. Penalty shots. Rough waters offshore
- Abstracts: Religious texts, moral prescriptions and economy: the case of interest. The Federal Deposit Insurance Corporation Improvement Act event in the bank commercial loan market